Abstract:A complex network precisely regulates the cell cycle through the G1, S, G2, and M phases and is the basis for cell division under physiological and pathological conditions. On the one hand, the transition from one phase to another as well as the progression within each phase is driven by the specific cyclin-dependent kinases (CDKs; e.g., CDK1, CDK2, CDK4, CDK6, and CDK7), together with their exclusive partner cyclins (e.g., cyclin A1, B1, D1-3, and E1). On the other hand, these phases are negatively regulated by endogenous CDK inhibitors such as p16ink4a, p18ink4c, p19ink4d, p21cip1, and p27kip1. In addition, several checkpoints control the commitment of cells to replicate DNA and undergo mitosis, thereby avoiding the passage of genomic errors to daughter cells. CDKs are often constitutively activated in cancer, which is characterized by the uncontrolled proliferation of transformed cells, due to genetic and epigenetic abnormalities in the genes involved in the cell cycle. Moreover, several oncogenes and defective tumor suppressors promote malignant changes by stimulating cell cycle entry and progression or disrupting DNA damage responses, including the cell cycle checkpoints, DNA repair mechanisms, and apoptosis. Thus, genes or proteins related to cell cycle regulation remain the main targets of interest in the treatment of various cancer types, including hematologic malignancies. In this context, advances in the understanding of the cell cycle regulatory machinery provide a basis for the development of novel therapeutic approaches. The present article summarizes the pathways as well as their genetic and epigenetic alterations that regulate the cell cycle; moreover, it discusses the various approved or potential therapeutic targets associated with the cell cycle, focusing on hematologic malignancies.

Cyclins and cdks in development and cancer: a perspective

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer.

Cell cycle, CDKs and cancer: a changing paradigm

Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors

Cell cycle regulation and anticancer drug discovery

A review on the role of cyclin dependent kinases in cancers

Cell Cycle Regulation and Hematologic Malignancies

Targeting CDK7 in oncology: The avenue forward.

Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis

Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

The double dealing of cyclin D1

DNA Damage Checkpoint Recovery and Cancer Development

Out of the Cycle: Impact of Cell Cycle Aberrations on Cancer Metabolism and Metastasis

CYCLINS AND CELL CYCLE CHECKPOINTS

CDK4 and CDK6 kinases: From basic science to cancer therapy

Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.

In my end is my beginning: control of end resection and DSBR pathway ‘choice’ by cyclin-dependent kinases

Why minimal is not optimal: Driving the mammalian cell cycle—and drug discovery—with a physiologic CDK control network

Development of Cell-Cycle Inhibitors for Cancer Therapy

Proliferation, cell cycle and apoptosis in cancer